bristol myers squibb news - Search News

Bristol Myers Squibb, Schizophrenia

Seeking Alpha · 6h

Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite potential risks. Read more on BMY here.

Bloomberg on MSN · 21h

Bristol Myers Gets US Nod for First New Schizophrenia Drug Type in Decades

Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions with the serious mental disorder.

Reuters on MSN · 21h

Bristol Myers wins US FDA approval for new type of schizophrenia drug

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades. The labeling information of the treatment,

19h

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

1d

Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

16h

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...

14hon MSN

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

2d

Bristol Myers Squibb Vs. AbbVie Stock

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

A new kind of drug for schizophrenia promises fewer side effects

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results